Update 05/03/21 CTXR now up over 20% following our coverage last week. "A rapid gain in market value can also release the sharks (short interest tra...
New Report Coming Tomorrow at Market Open on One of Our Favorite’s
We would not typically issue another report so soon after a big report like the last. However, the timing looks ideal for a potential squeeze. Good da...
Is the Biden Administration, Congress, and the FDA Declaring War on Nicotine? This $5 Stock Could Become a Home Run Overnight.
“22nd Century is in a very enviable – and near standalone - position to capitalize on the global combustible market that is valued at more than $700 b...
Be Ready for an Opportunity to Get Early Access to a Big 2021 Trading Story
"The wait is almost over, this report will be issued at the opening bell tomorrow, Monday 4/26/21."
Vanguard and Blackrock Lead a List of 42 Institutional Investor’s in this Company. Proprietary Biotech Actinium Pharma (NYSE: ATNM)
Update 3/25/21 (News out today) Actinium Announces Completion of Enrollment of Second Dose Cohort in Actimab-A Venetoclax Combination Trial for Patien...
Bionano Genetics (BNGO) Genetics Technology Sector Report
Good day everyone, Bionano Genomics, Inc. (NASDAQ: BNGO). Bionano Genomics operates as a life sciences instrumentation company in the genome analysis ...
For Ten Years the Mayo Clinic has Assisted in Product Development for Biosig’s Pure EP System. Now the Revenues have Begun.
The Mayo Clinic has a Pure EP System, they’ve been working with BioSig on product development for ten years.
The Future of Biotech is mRNA (Messenger RNA)
The successful use of mRNA in the development of the covid-19 vaccines will likely spur further investment and development toward treatments for other...
Genprex (NASDAQ: GNPX) Completes Another Milestone
We believe GNPX has just gotten started. Their ONCOPREX delivery system and the REQORSA technology are proprietary and no one else has anything like i...
These “Tiny Bubbles” from Genprex (GNPX) Could Beat Cancer
The FDA granted Fast Track Designation for REQORSA in combination with AstraZeneca’s Tagrisso for the treatment of non-small cell lung cancer.
